Anticimex vs. Aptive: Two PE-backed strategies, very different buyers
Anticimex and Aptive are both PE-backed pest control platforms pursuing aggressive growth — but their acquisition strategies, target profiles, and integration approaches are fundamentally different. Texas operators considering a sale need to understand which buyer's thesis fits their business.
Choose Anticimex if...
- ✓ You want the highest possible multiple — Anticimex pays 1.3–1.8×, among the best in market
- ✓ Your business is $2M+ revenue — Anticimex doesn't move on very small operators
- ✓ You have termite or commercial revenue — their thesis values recurring contracted books
- ✓ You want to retain your management team and brand longer post-acquisition
Choose Aptive if...
- ✓ Your book is primarily residential general pest — that's Aptive's core product
- ✓ You're in the $500K–$2M range — Aptive's deal team operates at smaller sizes
- ✓ You have a mosquito add-on — Aptive is actively building mosquito route density
- ✓ You operate in a Texas market where Aptive has existing D2D presence
Anticimex is the better buyer for operators with established recurring books and multi-service revenue. Aptive is the better buyer for residential-only operators who want to sell quickly and are in markets where Aptive's D2D teams already operate. The critical PE context: both firms are approaching exit windows (2026–2028), which means acquisition pace will increase and valuations may firm as each platform tries to maximize EBITDA before a sale or IPO. This is a good time to have both conversations.
Track Anticimex and Aptive deal activity in Texas
PestBrief's M&A signals flag operators who are being approached by PE-backed acquirers — before the deal closes.